Lymphoma  >>  Phase 2
Welcome,         Profile    Billing    Logout  

770 Trials

   Remove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lymphoma
IDA53, NCT03734198: Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction

Active, not recruiting
2
29
Europe
Ibrutinib, Ibrutinib treatment, Daratumumab, Daratumumab perfusion
French Innovative Leukemia Organisation, Janssen, LP
Relapsed or Refractory Chronic Lymphocytic Leukemia
06/24
06/26
COPA-R-CHOP, NCT04263584: Copanlisib in Combination With Rituximab and CHOP Chemotherapy in Patients With Previously Untreated DLBCL

Active, not recruiting
2
62
Europe
Copanlisib, R-CHOP Chemotherapy
University Hospital Muenster, Bayer
Diffuse Large B Cell Lymphoma
04/25
04/25
NCT04416451: A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma

Active, not recruiting
2
6
US
Rituximab, Venetoclax
Memorial Sloan Kettering Cancer Center, AbbVie
Marginal Zone Lymphoma
06/24
06/24
NCT04842877 / 2020-005225-81: Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma

Active, not recruiting
2
141
Europe
Valemetostat tosylate, DS-3201b
The Lymphoma Academic Research Organisation, Daiichi Sankyo
Lymphoma, B-Cell
10/24
10/24
NCT02194751: Oncoquest-L Vaccine in Patients With Previously Untreated Stage III or IV, Asymptomatic, Non-bulky Follicular Lymphoma

Not yet recruiting
2
30
US
Oncoquest-L vaccine
XEME Biopharma Inc.
Follicular Lymphoma
06/24
06/26
NCT05096234: 18F-F-AraG PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in Lymphoma

Recruiting
2
6
US
[ 18F]F-AraG PET, [ 18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D- arabinofuranosylguanine; trade name VisAcT)
Stanford University, CellSight Technologies, Inc.
Non-Hodgkin's Lymphoma
06/24
06/24
NCT05316246: Efficacy and Safety of BV With Tislelizumab for the Treatment of CD30+ Relapsed/Refractory NK/T-cell Lymphoma

Not yet recruiting
2
40
NA
Brentuximab Vedotin in Combination with Tislelizumab
Shanghai Zhongshan Hospital, Takeda, BeiGene
NK/T Cell Lymphoma Nos
06/24
12/24
IntriNSiC, NCT05329792 / 2021-006041-36: L19IL2/L19TNF in Skin Cancer Patients

Recruiting
2
70
Europe
L19IL2/L19TNF, bifikafusp alfa/onfekafusp alfa
Philogen S.p.A., Philogen S.p.A.
BCC - Basal Cell Carcinoma, SCC - Squamous Cell Carcinoma, Merkel Cell Carcinoma, Keratoacanthoma of Skin, Malignant Adnexal Tumors of the Skin (MATS), Tumors From Cutaneous T-cell Lymphoma (CTCL), Kaposi Sarcoma
06/24
12/24
NCT05852717: Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma

Recruiting
2
32
US
AutoSCT OR CAR T-cell Therapy, Autologous transplant, chimeric antigen receptor (CAR) T-cell, GDP, Epcoritamab
Dipenkumar Modi, Genmab
Large Cell Lymphoma, Diffuse, Relapsed Cancer, Refractory Cancer
06/24
06/25
NCT04747236: Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL

Recruiting
2
50
US
Azacytidine, Vidaza, Romidepsin, Istodax, Belinostat, Beleodaq, Pralatrexate, Folotyn, Gemcitabine, Gemzar
University of Virginia, Celgene
PTCL
12/26
06/28
NCI-2024-00054, NCT06252675: Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

Recruiting
2
50
US
Obinutuzumab, Anti-CD20 Monoclonal Antibody R715, huMAB(CD20), RO5072759, Glofitamab, Anti-CD3 Bispecific Monoclonal Antibody RO7082859, RO7082859, Pirtobrutinib, LOXO-305, Tumor Imaging, FDG-PET, Computed Tomography (CT), Biospecimen Collection, Biological Sample Collection, ClonoSeq Assay, ClonoSeq, Bone Marrow Biopsy, Biopsy of Bone Marrow
C. Babis Andreadis, Eli Lilly and Company, Genentech, Inc., Adaptive Biotechnologies
Mantle Cell Lymphoma
07/28
07/28
NCT03474744 / 2017-003150-16: Copanlisib and Rituximab in Marginal Zone Lymphoma Patients

Active, not recruiting
2
36
Europe
Copanlisib, Aliqopa, Rituximab, Truxima
Christian Buske, University of Ulm, Optimapharm, X-act Cologne Clinical Research GmbH, Zentrum für Klinische Studien Ulm, Celltrion Healthcare Co., LTD, Bayer
Marginal Zone Lymphoma
06/24
12/29
BGB-3111-218, NCT05068440: Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib

Recruiting
2
66
RoW
Zanubrutinib, BGB-3111, Brukinsa
BeiGene
Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma
12/24
12/24
NCI-2022-03831, NCT05357794: Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides

Recruiting
2
30
US
Brentuximab vedotin, SGN-35, Adcetris
M.D. Anderson Cancer Center, Seagen Inc.
Mycosis Fungoides
06/24
06/24
NCT05180097: Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

Recruiting
2
84
Canada
Gemcitabine, Dexamethasone, Cisplatin, Brentuximab vedotin, Pembrolizumab
Canadian Cancer Trials Group, Merck Sharp & Dohme LLC, Seagen Inc.
Hodgkin Lymphoma
06/25
06/26
NCT01316523: Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's Lymphoma

Active, not recruiting
2
30
US
Rituximab, Rituxan, Lenalidomide, Revlimid
University of California, Davis, Celgene
Non Hodgkin's Lymphoma
07/24
12/24
(Cohort 3) ZUMA-2, NCT04880434: Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)

Active, not recruiting
2
90
Europe, US
Fludarabine, Cyclophosphamide, Brexucabtagene autoleucel, KTE-X19, TECARTUS™
Kite, A Gilead Company
Relapsed/Refractory Mantle Cell Lymphoma
11/23
10/38
NAVAL-1, NCT05011058: An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas

Recruiting
2
140
Europe, Canada, US, RoW
Nanatinostat in combination with valganciclovir
Viracta Therapeutics, Inc.
Epstein-Barr Virus Associated Lymphoproliferative Disorder, EBV-Related PTLD, EBV Related Non-Hodgkin's Lymphoma, EBV-Positive DLBCL, NOS, EBV Associated Lymphoma, EBV Related PTCL, NOS
07/25
12/26
NCT06458439: Epcoritamab-CAR T Cells for Large B-cell Lymphomas

Not yet recruiting
2
31
US
Epcoritamab, GEN3013, DuoBody -CD3xCD20
Abramson Cancer Center at Penn Medicine, Genmab
Lymphoma, Non-Hodgkin, Relapsed Diffuse Large B Cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma, Transformed Indolent Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
10/27
12/27
NCT06390319: Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

Not yet recruiting
2
145
US
Dexamethasone, Decadron, Hexadrol®, Vincristine, Vincristine Sulfate, Oncovin, Daunorubicin, Daunomycin, Calaspargase pegol, ASPARLAS, Dasatinib, Sprycel®, Venetoclax, Venclexta®, Bortezomib, Velcade®, Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine), IT MHA, Cyclophosphamide, Cytoxan®, Cytarabine, Ara-C, Cytosine arabinoside, Mercaptopurine, 6-MP, Nelarabine, Arranon, Atriance, Methotrexate, Trexall®, Thioguanine, 6-thioguanine, Tabloid®
St. Jude Children's Research Hospital, AbbVie
T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoma, Mixed Phenotype Acute Leukemia
12/27
12/33
NCT01258933: Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy

Active, not recruiting
2
44
US
Ofatumumab, Arzerra
M.D. Anderson Cancer Center, GlaxoSmithKline
Leukemia, Lymphoma
07/24
07/24
NCI-2018-02699, NCT03749018: Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

Active, not recruiting
2
30
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16-213, VP-16, VP-16-213, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisonum, Prednitone, Promifen, Servisone, SK-Prednisone, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, RTXM83, Vincristine Sulfate, Kyocristine, Leurocristine sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
David Bond, MD, Bristol-Myers Squibb
Aggressive Non-Hodgkin Lymphoma, Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Ann Arbor Stage II B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Indolent Non-Hodgkin Lymphoma, Mediastinal B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, Transformed Non-Hodgkin Lymphoma
07/24
07/24
NCT04594798: A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL

Recruiting
2
39
US
Polatuzumab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone
University of Rochester, Genentech, Inc.
DLBCL, Lymphoma, B-Cell
07/24
07/24
NCT03618550: Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

Recruiting
2
69
US
pembrolizumab, gemcitabine, vinorelbine, liposomal doxorubicin, Stem cell mobilization and collection
Memorial Sloan Kettering Cancer Center, Merck Sharp & Dohme LLC
Hodgkin Lymphoma, Relapsed or Refractory Hodgkin Lymphoma
08/24
08/24
NCT04998669: Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma

Recruiting
2
39
US
Loncastuximab tesirine, ADCT-402, Rituximab, Rituxan
Juan P. Alderuccio, MD, ADC Therapeutics S.A.
Follicular Lymphoma
08/24
08/27
NCI-2021-12489, NCT05169658: Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma

Recruiting
2
42
US
Mosunetuzumab, 1905409-39-3, Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody BTCT4465A, BTCT 4465A, BTCT-4465A, BTCT4465A, CD20/CD3 BiMAb BTCT4465A, RG 7828, RG-7828, RG7828, RO7030816, Lunsumio, Mosunetuzumab-axgb, Obinutuzumab, 949142-50-1, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Polatuzumab Vedotin, 1313206-42-6, ADC DCDS4501A, Antibody-Drug Conjugate DCDS4501A, DCDS4501A, FCU 2711, polatuzumab vedotin-piiq, Polivy, RG7596, Ro 5541077-000
University of Washington, Genentech, Inc.
Non-Hodgkin Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma, Marginal Zone Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
12/25
12/25
NCT06093841: Relmacabtagene Autoleucel as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL

Not yet recruiting
2
46
RoW
Relmacabtagene Autoleucel, JWCAR029, Fludarabine, Cyclophosphamide
Shanghai Ming Ju Biotechnology Co., Ltd.
Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma Grade 3B, High-grade B-cell Lymphoma, Mediastinal B-Cell Diffuse Large Cell Lymphoma
08/24
02/27
GOLSEEK-2, NCT06425302: A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma

Not yet recruiting
2
90
Europe, Canada, US, RoW
Golcadomide, CC-99282, BMS-986369, Rituximab, Mabthera, Cyclophosphamide, Endoxan, Doxorubicin, Caelyx, pegylated liposomal doxorubicin, PLD, Vincristine, Prednisone, Bendamustine
Celgene
Lymphoma, Follicular
11/26
11/28
NCT05436223: Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma

Recruiting
2
100
RoW
Human CD19Targeted T Cells Injection, CD19 CAR-T
Hrain Biotechnology Co., Ltd., Shanghai Zhongshan Hospital
B-cell Non-Hodgkin's Lymphoma
08/24
08/26
KEYVIBE-004, NCT05005442 / 2021-001700-15: A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, )

Active, not recruiting
2
180
Europe, Canada, US, RoW
Pembrolizumab/vibostolimab coformuation, MK7684A
Merck Sharp & Dohme LLC
Hematological Malignancies
08/24
08/24
BDHRT001, NCT04992377: R-EPOCH in Combination With Ibrutinib for Patients With Classical RT of CLL

Not yet recruiting
2
30
RoW
R-EPOCH in Combination With Ibrutinib
Institute of Hematology & Blood Diseases Hospital, Xian-Janssen Pharmaceutical Ltd.
Richter Transformation
08/24
08/25
NCT05583149: Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas

Recruiting
2
27
US
ACALABRUTINIB, Calquence, LISOCABTAGENE MARALEUCEL, Breyanzi, Lymphodepleting chemotherapy, cyclophosphamide and fludarabine
Patrick C. Johnson, MD, AstraZeneca
Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL, Diffuse Large B-cell Lymphoma (DLBCL), De Novo or Transformed Indolent B-cell Lymphoma, DLBCL, Nos Genetic Subtypes, T Cell/Histiocyte-rich Large B-cell Lymphoma, EBV-Positive DLBCL, Nos, Primary Mediastinal [Thymic] Large B-cell Lymphoma (PMBCL), High-Grade B-Cell Lymphoma, Nos, C-MYC/BCL6 Double-Hit High-Grade B-Cell Lymphoma, Grade 3b Follicular Lymphoma, C-MYC/BCL2 Double-Hit High-Grade B-Cell Lymphoma
03/25
03/29
KEYNOTE B68, NCT04875195: A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)

Active, not recruiting
2
66
Europe, Canada, US, RoW
Pembrolizumab, MK-3475, SCH 900475, KEYTRUDA®
Merck Sharp & Dohme LLC
Hodgkin's Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL)
12/23
12/25
NCT04533581: Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma (NHL)

Active, not recruiting
2
61
Japan
ME-401
Kyowa Kirin Co., Ltd.
Indolent B-cell Non-Hodgkin's Lymphoma
09/24
09/24
NCT02570542: Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Active, not recruiting
2
59
US
leukapheresis, Plerixafor, carmustine, etoposide, cytarabine, melphalan, BEAM chemotherapy, Autologous Stem Cell Transplantation
Memorial Sloan Kettering Cancer Center, Columbia University, NorthShore University HealthSystem, University of Rochester, Medical College of Wisconsin, University of Nebraska, Sanofi, University Hospitals Seidman Cancer Center
Diffuse Large B-cell Lymphoma (DLBCL), Relapsed Diffuse Large B-cell Lymphoma (DLBCL), Refractory Diffuse Large B-cell Lymphoma (DLBCL)
10/24
10/24
P+R-ICE, NCT05221645: Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting
2
65
Europe
Pembrolizumab, KEYTRUDA, Rituximab, MabThera, Ifosfamide, Carboplatin, Etoposide
University of Southampton, Merck Sharp & Dohme LLC
Diffuse Large B Cell Lymphoma
10/24
12/25
NCT05563844: Study of Purinostat Mesylate for Injection in the Treatment of Diffuse Large B-cell Lymphoma (DLBCL)

Recruiting
2
30
RoW
PM 8.4 mg/m2, PM 11.2 mg/m2
Chengdu Zenitar Biomedical Technology Co., Ltd
Diffuse Large B Cell Lymphoma，DLBCL
10/24
05/25
PACE-CLL, NCT05465876: Passive Antibodies Against COVID-19 With EVUSHELD in Vaccine Non-responsive CLL

Withdrawn
2
200
Canada
EVUSHELD
Sunnybrook Health Sciences Centre, AstraZeneca
Chronic Lymphocytic Leukemia, COVID-19
10/24
10/25
NCT04359784: Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Non-Hodgkin Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy

Recruiting
2
25
US
Anakinra, Kinaret, Kineret, rIL-1ra, rIL1RN, 143090-92-0, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, Radiographic Imaging, Positron Emission Tomography, PET scan, Computed Tomography, CAT Scan, Computed Axial Tomography, CT scan, Bone Marrow Aspiration, Bone Marrow Biopsy, Lumbar Puncture, LP, spinal tap, Biospecimen Collection, Biological Sample Collection
Fred Hutchinson Cancer Center, Swedish Orphan Biovitrum
B-Cell Non-Hodgkin Lymphoma
10/24
10/24
Actuate 1801, NCT03678883: 9-ING-41 in Patients With Advanced Cancers

Active, not recruiting
2
350
Europe, Canada, US
9-ING-41, Gemcitabine - 21 day cycle, Gemzar, Doxorubicin., Doxil, Adriamycin, Lomustine, CCNU, Gleostine, Carboplatin., Paraplatin, Nab paclitaxel., Abraxane, Protein-bound paclitaxel, Nanoparticle albumin-bound paclitaxel, Paclitaxel., Taxol, Gemcitabine - 28 day cycle, Irinotecan, Camptosar
Actuate Therapeutics Inc.
Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma, Resistant Cancer, Neoplasm Metastasis, Neoplasm of Bone, Neoplasm, Breast, Neoplasm of Lung, Neoplasms,Colorectal, Neoplasms Pancreatic, Malignant Glioma, Malignancies, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Bone Cancer, Pancreas Cancer, Pancreatic Neoplasms, Breast Neoplasms, Acute T Cell Leukemia Lymphoma
11/24
11/25
Lemon-C, NCT04627753: Study of Lenalidomide/Rituximab Maintenance for Transplantation Ineligible Patients With PCNSL.

Recruiting
2
30
RoW
Rituximab, lenalidomide, Truxima Inj, Lenalid
Kim, Seok Jin, Celltrion, Samyang Biopharmaceuticals Corporation
Primary CNS Lymphoma
11/24
11/24
CLOVER-WaM, NCT02952508 / 2020-005297-10: Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia

Recruiting
2
120
Europe, US, RoW
Iopofosine I 131 single dose, I-131-CLR1404, CLR 131, Iopofosine I 131 multiple dose, Iopofosine I 131 fractionated dose
Cellectar Biosciences, Inc.
Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma, Central Nervous System Lymphoma
11/24
06/25
NCT05479994: Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Recruiting
2
97
RoW
BGB-11417, sonrotoclax
BeiGene
Leukemia, Lymphoma, Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma, Relapsed Chronic Lymphocytic Leukemia
04/25
08/27
CRU3, NCT03505554: A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma

Recruiting
2
12
Europe
Lorlatinib, PF-06463922
University of Milano Bicocca, Pfizer
Anaplastic Large Cell Lymphoma, ALK-Positive
12/24
12/24
BRAWM, NCT04624906: Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia

Active, not recruiting
2
59
Canada
Acalabrutinib, Calquence, Bendamustine, Treanda, Rituximab, Rituxan
Sunnybrook Health Sciences Centre, AstraZeneca
Waldenstrom Macroglobulinemia
12/24
03/30
NCT04750941: Study of Copanlisib and Ketogenic Diet

Active, not recruiting
2
1
US
Copanlisib, Aliqopa, Ketogenic Diet
Columbia University, Bayer
Follicular Lymphoma, Endometrial Cancer
12/24
12/24
NCT04788043: Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma

Active, not recruiting
2
8
US
Magrolimab, Hu5F9-G4, ONO-7913, anti-CD47 monoclonal antibody Hu5F9-G4, Pembrolizumab, Keytruda, MK-3475, SCH 900475, anti-PD-1 monoclonal antibody MK-3475, PET/CT, Positron Emission Tomography - Computed Tomography (PET/CT)
Stanford University, Merck Sharp & Dohme LLC
Hodgkin Lymphoma, Classic Hodgkin Lymphoma, Relapsed Classical Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
12/24
12/27
NCT05633615: Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting
2
396
US
Axicabtagene Ciloleucel, KTE C19, KTE-C19, KTE-C19 CAR, Yescarta, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Fludarabine, Fluradosa, Lisocabtagene Maraleucel, Anti-CD19-CAR Genetically Engineered Autologous T Lymphocytes JCAR017, Anti-CD19-CAR Genetically Engineered Autologous T-lymphocytes JCAR017, Autologous Anti-CD19-EGFRt-4-1BB-zeta-modified CAR CD8+ and CD4+ T-lymphocytes JCAR017, Breyanzi, JCAR 017, JCAR017, Mosunetuzumab, Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody BTCT4465A, BTCT 4465A, BTCT-4465A, BTCT4465A, CD20/CD3 BiMAb BTCT4465A, RG 7828, RG-7828, RG7828, RO7030816, Patient Observation, Active Surveillance, deferred therapy, expectant management, Observation, Watchful Waiting, Polatuzumab Vedotin, ADC DCDS4501A, Antibody-Drug Conjugate DCDS4501A, DCDS4501A, FCU 2711, polatuzumab vedotin-piiq, Polivy, RG7596, Ro 5541077-000, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Tisagenlecleucel, CART-19, CART19, CTL019, CTL019 T-cells, Kymriah, Tisagenlecleucel-T
SWOG Cancer Research Network, National Cancer Institute (NCI), Genentech, Inc.
Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Transformed Follic Lymph to Diff Large B-Cell Lymphoma, Transformed Marg Zone Lymph to Diff Large B-Cell Lymphoma
12/25
12/29
NCT01446133: Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL)

Active, not recruiting
2
120
US
Rituximab, Rituxan, Lenalidomide, CC-5013, Revlimid
M.D. Anderson Cancer Center, Celgene Corporation
Leukemia, Lymphoma
12/24
12/24
STARTRK-2, NCT02568267 / 2015-003385-84: Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

Checkmark From STARTRK-2 trial in NTRK+ solid tumors
Oct 2019 - Oct 2019: From STARTRK-2 trial in NTRK+ solid tumors
Checkmark STARTRK-2 trial in NTRK+ solid tumors at ESMO 2018 [screenshot]
Oct 2018 - Oct 2018: STARTRK-2 trial in NTRK+ solid tumors at ESMO 2018 [screenshot]
Checkmark Integrated analysis of 3 trials (STARTRK-2, STARTRK-1, ALKA-372-001) in NTRK fusion-positive solid tumors
More
Active, not recruiting
2
534
Europe, Japan, US, RoW
Entrectinib, RXDX-101
Hoffmann-La Roche
Breast Cancer, Cholangiocarcinoma, Colorectal Cancer, Head and Neck Neoplasms, Lymphoma, Large-Cell, Anaplastic, Melanoma, Neuroendocrine Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Papillary Thyroid Cancer, Primary Brain Tumors, Renal Cell Carcinoma, Sarcomas, Salivary Gland Cancers, Adult Solid Tumor
12/24
04/25
TAPUR, NCT02693535: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Recruiting
2
3791
US
Palbociclib, Ibrance, Sunitinib, Sutent, Temsirolimus, Torisel, Trastuzumab and Pertuzumab, Herceptin and Perjeta, Vemurafenib and Cobimetinib, Zelboraf and Cotellic, Regorafenib, Stivarga, Olaparib, Lynparza, Pembrolizumab, Keytruda, Nivolumab and Ipilimumab, Opdivo and Yervoy, Abemaciclib, Verzenio, Talazoparib, Talzenna, Atezolizumab and PHESGO, Tecentriq and PHESGO, Atezolizumab and Talazoparib, Tecentriq and Talzenna, Entrectinib, Rozlytrek, Larotrectinib, Vitrakvi, Tucatinib plus Trastuzumab Subcutaneous (SC), Tukysa and Herceptin Hylecta, Futibatinib, Lytgobi
American Society of Clinical Oncology, AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Inc., Merck Sharp & Dohme LLC, Pfizer, Boehringer Ingelheim, Seagen Inc., Taiho Oncology, Inc.
Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
12/24
12/25
DALY II USA, NCT04792489: / MB-CART2019.1 for DLBCL

Recruiting
2
110
US
zamtocabtagene autoleucel (MB-CART2019.1), Cyclophosphamide, Fludarabine, Bendamustine
Miltenyi Biomedicine GmbH
Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B Cell Lymphoma, High Grade B-cell Lymphoma (HGBCL), Primary Mediastinal B-cell Lymphoma (PMBCL), Transformed Lymphoma, Central Nervous System Lymphoma
12/24
12/26
UPCC 48420, NCT04889716: CAR-T Followed by Bispecific Antibodies

Recruiting
2
42
US
mosunetuzumab, RO7030816, BTCT4465A, Lunsumio, glofitamab, CD20 TCB, RO7082859, obinutuzumab, Gazyva, Gazyvaro, RO5072759, huMAb , GA101
Abramson Cancer Center at Penn Medicine, Genentech, Inc.
Large B-cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma
12/24
12/25
NCT05875428: Mitoxantrone Hydrochloride Liposome Injection in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Recruiting
2
104
RoW
Mitoxantrone Hydrochloride Liposome Injection
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Diffuse Large B-Cell Lymphoma
12/24
09/25
NCT02251548: A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia

Active, not recruiting
2
85
US
Ibrutinib, Imbruvica™, Fludarabine, Fludara, Cyclophosphamide, Cytoxan®, Neosar®, Rituximab, Rituxan®
Dana-Farber Cancer Institute, Pharmacyclics LLC., The Leukemia and Lymphoma Society, Blood Cancer Research Partnership
Chronic Lymphocytic Leukemia, Leukemia
01/25
01/26
ZUMA-5, NCT03105336 / 2017-001912-13: A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Checkmark Data from ZUMA-5 trial for R/R indolent NHL at ASH 2022
Dec 2022 - Dec 2022: Data from ZUMA-5 trial for R/R indolent NHL at ASH 2022
Checkmark Enrollment completion of P2 ZUMA-5 trial in r/r indolent NHL
Aug 2021 - Aug 2021: Enrollment completion of P2 ZUMA-5 trial in r/r indolent NHL
Checkmark Longer-term data in r/r follicular lymphoma from ZUMA-5 study
More
Active, not recruiting
2
159
Europe, US
axicabtagene ciloleucel, Axicab, Yescarta®, Cyclophosphamide, Fludarabine
Kite, A Gilead Company
Follicular Lymphoma, Marginal Zone Lymphoma, Indolent Non-Hodgkin Lymphoma
01/25
01/25
NCT04624633: Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL

Active, not recruiting
2
60
US
Acalabrutinib, Calquence, Umbralisib, RP5264, Ublituximab, LFB-R603
Jennifer R. Brown, MD, PhD, AstraZeneca, TG Therapeutics, Inc.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia
01/25
01/30
NCT02339922: Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma

Active, not recruiting
2
33
US
Ixazomib Citrate, MLN-9708, MLN9708, Ninlaro, Laboratory Biomarker Analysis, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, RTXM83, Rituximab Biosimilar SIBP-02
University of Washington, Millennium Pharmaceuticals, Inc.
Chronic Lymphocytic Leukemia, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia
01/25
01/31
KILT, NCT04984837: Study of Lacutamab in Peripheral T-cell Lymphoma

Checkmark KIR3DL2-expressing patients with r/r PTCL
Aug 2021 - Aug 2021: KIR3DL2-expressing patients with r/r PTCL
Recruiting
2
56
Europe
Lacutamab, Gemcitabine, Oxaliplatine
The Lymphoma Academic Research Organisation, Innate Pharma
Peripheral T Cell Lymphoma, Relapse/Recurrence
01/25
01/27
NCT03824483: Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)

Recruiting
2
230
US
Zanubrutinib, Obinutuzumab, GA101, Venetoclax, ABT-199
Memorial Sloan Kettering Cancer Center, BeiGene USA, Inc., Roche-Genentech, Massachusetts General Hospital
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Leukemia (SLL)
02/25
02/25
NCT04722172: A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL

Active, not recruiting
2
55
US
Acalabrutinib, Obinutuzumab
Memorial Sloan Kettering Cancer Center, AstraZeneca, Genentech, Inc.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
02/25
02/25
ReVenG, NCT04895436 / 2021-001037-39: Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

Recruiting
2
75
Europe, US, RoW
Venetoclax, Venclexta, ABT-199, GDC-0199, Obinutuzumab, GA101, Gazyva
AbbVie, F. Hoffmann-La Roche Ltd; German CLL Study Group (GCLLSG); Dana-Farber Cancer Institute
Chronic Lymphocytic Leukemia (CLL)
02/25
01/29
NCT05978739: Evaluating Different Doses of Orelabrutinib in MCL

Recruiting
2
40
RoW
Orelabrutinib High dose, Orelabrutinib Low dose
InnoCare Pharma Inc., Beijing InnoCare Pharma Tech Co., Ltd.
Mantle Cell Lymphoma
02/25
05/25
NCT04560322: Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL

Recruiting
2
40
US
Venetoclax, Venclexta, Obinutuzumab, Gazyva, Acalabrutinib, Calquence
Massachusetts General Hospital, Genentech, Inc.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
03/25
03/25
EPCORE DLBCL-3, NCT05660967: Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma

Recruiting
2
180
Europe, Japan, US, RoW
Epcoritamab, GEN3013, DuoBody®-CD3×CD20, EPKINLY™, Lenalidomide, Revlimid®
Genmab, AbbVie
Diffuse Large B-Cell Lymphoma
01/26
03/27
NCT05788289: A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma

Recruiting
2
39
US
Tafasitamab, Lenalidomide
Memorial Sloan Kettering Cancer Center, Incyte Corporation
Mantle Cell Lymphoma, MCL
03/25
03/25
LOTIS-9, NCT05144009: A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL)

Completed
2
41
Europe, US
Loncastuximab Tesirine, Zynlonta, ADCT-402, Rituximab
ADC Therapeutics S.A.
Diffuse Large B-cell Lymphoma
01/24
01/24
NCT04977024: SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer

Recruiting
2
240
US
COVID-19 Vaccine, Diagnostic Laboratory Biomarker Analysis, Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1, COH04S1, SARS-CoV-2 Vaccine COH04S1, sMVA-based SARS-CoV-2 Vaccine COH04S1, GEO-CM04S1
GeoVax, Inc., National Cancer Institute (NCI)
COVID-19 Infection, Hematopoietic and Lymphoid System Neoplasm, Leukemia, Lymphoma, Plasma Cell Myeloma
03/25
03/26
EPBSCH, NCT05961410: Eltrombopag for Peripheral Blood Stem Cell Harvest

Recruiting
2
46
RoW
Eltrombopag olamine, Revolade
National Taiwan University Hospital, Novartis
Lymphoma, Peripheral Blood Stem Cell Transplantation
03/25
03/26
ICP-CL-00901, NCT05552937: Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL

Recruiting
2
50
RoW
Tafasitamab and Lenalidomide
Beijing InnoCare Pharma Tech Co., Ltd.
DLBCL
04/25
04/27
EXPAND, NCT05714345: Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy

Active, not recruiting
2
70
Europe, US
ALLO-647, Fludarabine, Cyclophosphamide, ALLO-501A
Allogene Therapeutics
Relapsed/Refractory Large B Cell Lymphoma
02/24
10/29
NAHL, NCT05723055: Evaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma

Recruiting
2
9
US
Axatilimab, SNDX6532, Nivolumab, OPDIVO
University of Utah, Incyte Corporation
Hodgkin Lymphoma
04/25
04/28
NCT03990961: Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL)

Recruiting
2
13
US
Pembrolizumab, Keytruda
University of Chicago, Merck Sharp & Dohme LLC
Diffuse Large B Cell Lymphoma, Lymphoma
04/25
04/25
NCI-2022-07625, NCT05536349: Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)

Recruiting
2
60
US
Pirtobrutinib, Obinutuzumab, GA101, Gazyva, RO5072759, Venetoclax, ABT-199, GDC-0199, Valacyclovir, Allopurinol
M.D. Anderson Cancer Center, Loxo Oncology, Inc., The Leukemia and Lymphoma Society
Leukemia
04/25
04/25
NCT04419519: Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax

Recruiting
2
80
US
Venetoclax monotherapy, Venetoclax with anti CD20 monoclonal antibody
Memorial Sloan Kettering Cancer Center, Adaptive Biotechnologies
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
05/25
05/25
CHARIOT, NCT04268706: Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma

Active, not recruiting
2
97
US
CD30.CAR-T, Fludarabine, Fludara, Bendamustine, Bendeka
Tessa Therapeutics
Hodgkin Lymphoma, Adult, Hodgkin Disease Recurrent, Hodgkin Disease Refractory, Hodgkin Disease, Pediatric
05/25
03/37
NCT04745234 / 2020-004537-20: Mogamulizumab Q4week Dosing in Participants With R/R CTCL

Active, not recruiting
2
34
Europe, US
Mogamulizumab, 0761, KW0761, Poteligeo
Kyowa Kirin, Inc.
Cutaneous T-Cell Lymphoma, Relapsed, Cutaneous T-Cell Lymphoma Refractory
05/25
05/25
NCT05190705: Loncastuximab Tesirine in WM

Recruiting
2
36
US
Loncastuximab Tesirine, Zynlonta, Dexamethasone, Decadron, Dexamethasone Intensol, Dexpak, Taperpak
Shayna Sarosiek, MD, ADC Therapeutics S.A.
Waldenstrom Macroglobulinemia
05/25
08/27
RW-HPN-MF-01, NCT05872854: Treatment of Mycosis Fungoides With Hypericin Ointment and Visible Light

Recruiting
2
50
US
Hypericin, HyBryte, SGX301, Visible Light, Fluorescent light
Ellen Kim, MD, Soligenix
Cutaneous T Cell Lymphoma, Mycosis Fungoides
05/25
05/25
NCT03179930: Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas

Active, not recruiting
2
47
US
Entinostat, Pembrolizumab
Memorial Sloan Kettering Cancer Center, Merck Sharp & Dohme LLC, Syndax Pharmaceuticals
Lymphoma, Relapsed, Refractory
06/25
06/25
GO43075, NCT04980222 / 2021-001647-28: A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma

Active, not recruiting
2
46
Europe, US
Glofitamab, Tocilizumab, Doxorubicin, Vincristine, Prednisone, Rituximab, Cyclophosphamide
Hoffmann-La Roche
Lymphoma
06/25
06/25
waveLINE-004, NCT05144841: A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)

Active, not recruiting
2
140
Europe, Canada, US, RoW
MK-2140 (zilovertamab vedotin)
Merck Sharp & Dohme LLC
Relapsed or Refractory Diffuse Large B-Cell Lymphoma
06/25
06/25
NCT05900765: A Study of Zimberelimab(GLS-010) Combined With AVD for Newly Diagnosed Early-stage Hodgkin's Lymphoma

Recruiting
2
54
RoW
Zimberelimab 240mg, GLS-010
Sun Yat-sen University, Guangzhou Gloria Biosciences Co., Ltd.
Classical Hodgkin Lymphoma
06/25
06/26
NCT03587844: Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients

Recruiting
2
58
US
brentuximab vedotin
Memorial Sloan Kettering Cancer Center, Seagen Inc.
Mycosis Fungoides, Lymphomatoid Papulosis, Sezary Syndrome
07/25
07/25
NCT04570423: A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy

Recruiting
2
40
US
Eflapegrastim, Rolontis®, SPI-2012, Chemotherapy
Spectrum Pharmaceuticals, Inc
Solid Tumors, Lymphoma
10/27
10/27
NCT05575973: Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma

Not yet recruiting
2
55
RoW
Mitoxantrone Hydrochloride Liposome, Rituximab, Lenalidomide
Jianfeng Zhou, CSPC Ouyi Pharmaceutical Co., Ltd.
Diffuse Large B-cell Lymphoma
07/25
10/25
NCT04501939: Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax

Active, not recruiting
2
5
US
Cirmtuzumab, Zilovertamab, Venetoclax, VENCLEXTA
University of California, San Diego, Oncternal Therapeutics, Inc
Chronic Lymphocytic Leukemia
07/25
07/25
NCT05422066: Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma

Hourglass Jan 2023 - Dec 2023 : Market entry for endometrial cancer
Recruiting
2
50
RoW
Selinexor, ATG-010, Xpovio, Rituximab, RiTUXimab Injection, Cyclophosphamide, Cyclophosphamide Injection, Doxorubicin, Doxorubicin Hydrochloride, Vincristine, Vincristine Injection, Prednisone, Prednisone Oral Product
Li Zhiming, Antengene Corporation
DLBCL Germinal Center B-Cell Type
07/25
12/25
BrUOG 401, NCT04792502: Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma

Recruiting
2
52
US
Mosunetuzumab, Lenalidomide
Brown University, Genentech, Inc.
Follicular Lymphoma, Marginal Zone Lymphoma, B-cell Lymphoma
08/25
08/27
NCT03207555: Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL)

Active, not recruiting
2
29
US
Ibrutinib, PCI-32765, Imbruvica
M.D. Anderson Cancer Center, Pharmacyclics LLC.
Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia
08/25
08/25
NCT01508312: Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma

Checkmark ASCO 2016
May 2016 - May 2016: ASCO 2016
Completed
2
46
US
brentuximab vedotin (SGN-35), Brentuximab Vedotin (SGN-35)
Memorial Sloan Kettering Cancer Center, Seagen Inc., Hôpitaux Universitaires Henri Mondor, France
Hodgkin's Lymphoma
03/24
03/24
NCT04679012: Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation

Recruiting
2
20
US
Polatuzumab Vedotin, Polivy, Rituximab, Rituxan, chimeric anti-CD20 monoclonal antibody, Etoposide, VP-16, VePesid, etopophos, toposar, Prednisone, Deltasone, Orasone, Paracort, Cortan, Cyclophosphamide, cytoxan, Hydroxydaunomycin, Doxorubicin Hydrochloride, Hydroxydoxorubicin Hydrochloride
Weill Medical College of Cornell University, Genentech, Inc.
Richter Syndrome, Chronic Lymphocytic Leukemia
09/25
09/26
NCT05453500: Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia

Recruiting
2
30
US
Bone Marrow Aspiration and Biopsy, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP-16, VP-16-213, VP16, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Riabni, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, rituximab-abbs, Rituximab-arrx, Rituximab-pvvr, RTXM83, Ruxience, Truxima, Tafasitamab, Immunoglobulin, Anti-(Human Cd19 Antigen) (Human-mus musculus Monoclonal MOR00208 Heavy Chain), Disulfide with Human-mus musculus Monoclonal MOR00208 .Kappa.-chain, Dimer, Monjuvi, MOR-00208, MOR00208, MOR208, Tafasitamab-cxix, XmAb5574, Vincristine, Leurocristine, VCR, Vincrystine
University of Washington, Incyte Corporation
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
09/25
09/30
FIRCE-1, NCT05972720: A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma

Recruiting
2
123
US
Fludarabine (Conditional therapy), Cyclophosphamide Monohydrate (Conditional therapy), firi-cel (Experimental drug)
CARGO Therapeutics
Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL)
09/25
12/26
NCT05025423: Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma

Recruiting
2
40
US
Venetoclax Oral Tablet [Venclexta], rituximab infusion [Rituxan], Bendamustine infusion
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, AbbVie
Mantle Cell Lymphoma
09/25
09/26
NCT05105841: Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
2
20
Japan
Venetoclax, Venclexta, ABT-199, GDC-0199, Ibrutinib, Imbruvica, Obinutuzumab, GA101, Gazyva, RO5072759
AbbVie
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
10/25
10/25
BGB-3111-215 , NCT04116437: Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment

Recruiting
2
90
US
Zanubrutinib, BGB-3111, BRUKINSA
BeiGene
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
10/25
10/25
REMoDL-A, NCT04546620: Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL)

Recruiting
2
453
Europe
R-CHOP, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone, R-CHOP + acalabrutinib, Acalabrutinib
University Hospital Southampton NHS Foundation Trust, AstraZeneca
Diffuse Large B Cell Lymphoma
01/27
07/27
NCT05168930: Zanubrutinib and Venetoclax in CLL (ZANU-VEN)

Recruiting
2
45
US
Venetoclax, Venclexta, Zanubrutinib, Brukinsa
Dana-Farber Cancer Institute, BeiGene
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
10/25
10/28
NCT05922904: PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma

Recruiting
2
50
US
Brentuximab vedotin, Doxorubicin Hydrochloride, Adriamycin PFS®, Adriamycin RDF™, Adriamycin®, Rubex®, Pembrolizumab, SGN-35, Adcetris, Dacarbazine, DTIC-Dome®
M.D. Anderson Cancer Center, Merck Sharp & Dohme LLC, Seagen Inc.
Hodgkin Lymphoma
10/25
10/25
 

Download Options